MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Lysosomal-driven reduction of alpha-synuclein aggregates in a neuron-like model of Parkinson’s disease

    S. Lucas-Del-Pozo, G. Uras, F. Fierli, AHV. Schapira (London, United Kingdom)

    Objective: To test whether PIKfyve inhibition results in a lysosomal-driven reduction of alpha-synuclein aggregates in a mutant neuroblastoma cell line overexpressing an aggregation-prone form of…
  • 2023 International Congress

    AAV5-miHTT gene therapy mediates sustained mutant huntingtin lowering in brain and cerebrospinal fluid of Huntington’s disease minipigs up to 5 years

    L. Van_der Bent, C. Brouwers, A. Stam, L. Spronck, J. Klíma, J. Juhásová, B. Levinská, S. Juhás, J. Motlík, M. Evers, Z. Ellederova, A. Valles (Amsterdam, Netherlands)

    Objective: Our objective is to assess long-term safety of and durability of an adeno-associated viral vector serotype 5 encoding an engineered miRNA (AAV5-miHTT) targeting human…
  • 2023 International Congress

    Innovating Clinical Trial Design to Accelerate Assessment of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Initiative

    G. Mills, R. Chapman, S. Collins, R. Ellis-Doyle, C. Gonzalez-Robles, M. Zeissler, O. Bandmann, R. Barker, J. Carpenter, J. Chataway, J. Duffen, S. Gandhi, K. Mcfarthing, S. Mullin, A. Schapira, A. Schrag, C. Carroll, T. Foltynie (London, United Kingdom)

    Objective: To design an optimal multi-arm, multi-stage (MAMS) platform trial for disease-modifying therapies (DMTs) in Parkinson’s disease (PD). Background: The current clinical trials process cannot…
  • 2023 International Congress

    Age at Onset and Therapeutic Efficacy of Primidone in Essential Tremor Patients

    F. Jamal, G. Jackson, A. Sarwar, P. Mandava (Houston, USA)

    Objective: To study the therapeutic response of primidone in different age groups of Essential Tremor (ET) patients, based on age at onset. Background: Essential Tremor…
  • 2023 International Congress

    Design of a time-to-event study in GBA Parkinson’s Disease patients: Efficacy and safety of BIA 28-6156, an allosteric activator of beta-glucocerobridase (GCase)

    L. Magalhães, M. Fonseca, G. Castilla-Fernández, R. Costa, D. Simon, J. Holenz, N. Mendonça (Coronado, Portugal)

    Objective: To assess the efficacy of BIA 28-6156 in delaying clinically meaningful motor progression in PD patients who have a PD-risk associated variant in the…
  • 2023 International Congress

    Speech difficulties and dopaminergic neurodegeneration in Parkinson’s Disease

    S. Polychronis, B. Ribba, G. Nasios, E. Dardiotis, G. Pagano (Ioannina, Greece)

    Objective: To evaluate the association between speech difficulties and neurodegeneration of the putaminal dopaminergic system in people with early-stage treated with symptomatic therapy and advanced-stage…
  • 2023 International Congress

    Disorder of bulk lipid transfer? Lipid composition and distribution in cellular models of VPS13A disease

    K. Peikert, A. Spranger, E. Fischer, H. Glaß, B. Falkenburger, G. Miltenberger-Miltenyi, D. Tyteca, C. Klose, D. Grossmann, A. Hermann (Rostock, Germany)

    Objective: To study the overall lipid composition and distribution in red blood cells (RBCs) and neurons derived from VPS13A disease patients, a neurodegenerative disorder associated…
  • 2023 International Congress

    Screening and Treatment of Depression in Parkinson’s Disease Within Movement Disorders Centers

    C. Marras, D. Weintraub, J. Beck, A. Naito, Z. Meyer, N. Dahodwala, T. Davis, K. Mills, J. Miyasaki, S. Mantri, M. Neault, A. Brown, A. Allen, E. Nelson, H. Liu (Toronto, Canada)

    Objective: Implement depression screening using a validated instrument for people with Parkinson’s (PWP) as part of standard of care in the specialist movement disorders setting…
  • 2023 International Congress

    Effects of Boxing and conventional physiotherapy techniques in patients with PD: A randomized control study

    W. Kamel, M. Asala, A. Al-Tajalli, A. Al-Tammar, R. Alkhaldi, C. Ramos Jr, A. Mubarak (beni suef, Egypt)

    Objective: To determine the effectiveness of boxing vs. conventional physiotherapy techniques in improving the quality of movement, motor, cognitive functions in patients with PD. Background:…
  • 2023 International Congress

    Hereditary spastic paraplegia type 4 (SPG4): an international multicenter clinical and genetic study

    A. Orlacchio, E. Panza, R. Rumore, C. Montecchiani, F. Gaudiello, M. Stasi, A. Stigliano, M. Miele, R. Massa, M. Bassi, A. Tessa, F. Santorelli, A. Meyyazhagan, P. St George-Hyslop, J. Pedroso, O. Barsottini, H. Teive, R. Miyamoto, T. Kawarai (Rome, Italy)

    Objective: To describe the epidemiological, clinical, and genetic features of patients affected by hereditary spastic paraplegia (HSP) in an international cohort of affected individuals.To describe…
  • « Previous Page
  • 1
  • …
  • 133
  • 134
  • 135
  • 136
  • 137
  • …
  • 186
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley